Cargando…

Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022

This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Juan, Song, Rui, Yuan, Zheng, Xu, Zheng, Suo, Luodan, Wang, Qing, Li, Yuan, Gao, Yanlin, Li, Xiaomei, Chen, Xiaoyou, Wu, Jiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413898/ https://www.ncbi.nlm.nih.gov/pubmed/36016103 http://dx.doi.org/10.3390/vaccines10081215

Ejemplares similares

Difference of Clinical Characteristics in Patients with Omicron and Delta Variants of SARS-CoV-2 in Beijing, China
por: Tian, Di, et al.
Publicado: (2023)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
por: Zhang, Lei, et al.
Publicado: (2023)

Comparison of Omicron and Delta Variant Infection COVID-19 Cases — Guangdong Province, China, 2022
por: Hu, Ting, et al.
Publicado: (2022)

Reproduction Number of the Omicron Variant Triples That of the Delta Variant
por: Du, Zhanwei, et al.
Publicado: (2022)

Willingness of the General Public to Receive the COVID-19 Vaccine During a Second-Level Alert — Beijing Municipality, China, May 2020
por: Ma, Rui, et al.
Publicado: (2021)

Will New Variants Emerge after Delta and Omicron?
por: Yang, Zhen, et al.
Publicado: (2022)

Acceptability for the influenza virus vector COVID-19 vaccine for intranasal spray: A cross-sectional survey in Beijing, China
por: Ma, Yuan, et al.
Publicado: (2023)

Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents
por: Wang, Hao, et al.
Publicado: (2023)

The Quantification of Spike Proteins in the Inactivated SARS-CoV-2 Vaccines of the Prototype, Delta, and Omicron Variants by LC–MS
por: Xu, Kangwei, et al.
Publicado: (2023)

The First Outbreak of Omicron Subvariant BA.5.2 — Beijing Municipality, China, July 4, 2022
por: Feng, Zhaomin, et al.
Publicado: (2022)

Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants — China, May 21, 2021–February 28, 2022
por: Li, Mingshuang, et al.
Publicado: (2022)

Importation of SARS-CoV-2 Omicron variant in Beijing, China
por: Li, Fu, et al.
Publicado: (2022)

Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants
por: Jia, Liqiu, et al.
Publicado: (2022)

Antibody induced by one-dose varicella vaccine soon became weak in children: evidence from a cross-sectional seroepidemiological survey in Beijing, PRC
por: Suo, Luodan, et al.
Publicado: (2015)

A Local Cluster of Omicron Variant COVID-19 Likely Caused by Internationally Mailed Document — Beijing Municipality, China, January 2022
por: Zhang, Daitao, et al.
Publicado: (2022)

Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model
por: Yadav, Pragya D., et al.
Publicado: (2022)

Analysis of Factors Influencing the Clinical Severity of Omicron and Delta Variants
por: Zhao, Shanlu, et al.
Publicado: (2023)

Assessing the Transmissibility of the New SARS-CoV-2 Variants: From Delta to Omicron
por: Dong, Rui, et al.
Publicado: (2022)

Liver injury caused by SARS-CoV-2 Delta and Omicron-variant in Taiwan
por: Jang, Tyng-Yuan
Publicado: (2022)

Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccine
por: Lu, Changrui, et al.
Publicado: (2023)

Impacts of delta and omicron variants on inactivated SARS‐CoV‐2 vaccine‐induced T cell responses in patients with autoimmune diseases and healthy controls
por: Wang, Shuyi, et al.
Publicado: (2023)

Effect of Earlier Vaccination and a Two-Dose Varicella Vaccine Schedule on Varicella Incidence — Beijing Municipality, 2007–2018
por: Zhao, Dan, et al.
Publicado: (2021)

Will the COVID-19 pandemic end with the Delta and Omicron variants?
por: Wang, Chaoqi, et al.
Publicado: (2022)

Attitudes of vaccination service providers to the SARS-CoV-2 intranasal spray vaccine during the SARS-CoV-2 pandemic in China: A cross-sectional study
por: Cao, Yanlin, et al.
Publicado: (2023)

Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 – February 2022)
por: Petrone, Daniele, et al.
Publicado: (2023)

A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial
por: Cao, Yu, et al.
Publicado: (2022)

Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
por: Zhang, Yuntao, et al.
Publicado: (2022)

Monovalent vaccination with inactivated SARS-CoV-2 BA.5 protects hamsters against Omicron but not non-Omicron variants
por: Ong, Chon Phin, et al.
Publicado: (2023)

Clinical characteristics of abruptly increased paediatric patients with Omicron BF.7 or BA.5.2 in Beijing
por: Yu, Lei, et al.
Publicado: (2023)

Effectiveness of Inactivated COVID-19 Vaccines against COVID-19 Caused by the SARS-CoV-2 Delta and Omicron Variants: A Retrospective Cohort Study
por: Hua, Qiaoli, et al.
Publicado: (2022)

CRISPR‐Cas13d effectively targets SARS‐CoV‐2 variants, including Delta and Omicron, and inhibits viral infection
por: Liu, Zongzhi, et al.
Publicado: (2023)

GenomeBits insight into omicron and delta variants of coronavirus pathogen
por: Canessa, Enrique, et al.
Publicado: (2022)

Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
por: Lee, Richard Kuan-Lin, et al.
Publicado: (2022)

A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
por: Zhang, Xinghai, et al.
Publicado: (2022)

Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
por: Barbui, Tiziano, et al.
Publicado: (2022)

Comparative analysis of transmission and vaccine effectiveness in Omicron and Delta variant outbreaks in China
por: Li, Kangguo, et al.
Publicado: (2023)

Comparison of clinical characteristics between SARS-CoV-2 Omicron variant and Delta variant infections in China
por: Li, Qinggang, et al.
Publicado: (2022)

Temporal, age, and geographical variation in vaccine efficacy against infection by the Delta and Omicron variants in the community in France, December 2021 to March 2022
por: Blanquart, François, et al.
Publicado: (2023)

COVID-19 Vaccination Coverage among 42,565 Adults Amid the Spread of Omicron Variant in Beijing, China
por: Qin, Chenyuan, et al.
Publicado: (2023)

Modeling the Impact of Vaccination on COVID-19 and Its Delta and Omicron Variants
por: Wang, Jianbo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u83f22pg6akavjd5rqm9jk0mqu